A systematic approach to managing hypertension and the metabolic syndrome in primary care

Southern Medical Journal

Volumn 97, Issue 10, 2004, Pages 932-938

  Bestermann, William H ^a   Lackland, Daniel T ^a   Riehle, Jessica E ^a   Egan, Brent M ^a  

^a NONE

Author keywords

Cholesterol; Diabetes mellitus; Evidence based goals; Hypertension; Metabolic syndrome

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ADULT; AGED; ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC SYNDROME X; OBESITY; PATIENT EDUCATION; PRIMARY MEDICAL CARE;

AGED; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; METABOLIC SYNDROME X; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 6344236774     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000129923.83896.CC     Document Type: Article

References (46)

1. Lackland DT, Bachman DL, Carter TD, et al. The geographic variation in stroke incidence in two areas of the Southeastern Stroke Belt: the Anderson and Pee Dee Stroke Study. Stroke 1998;29:2061-2068.
2. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population: data from the Health Examination and Nutrition Survey, 1960 to 1991. Hypertension 1995;26:60-69.
3. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-723.
4. Hansen RC, Imperatore G, Bennett PH, et al. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002;51: 3120-3127.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
6. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 2001;24:454-459.
7. Egan BM, Lackland DT, Basile JN. American Society of Hypertension regional chapters: leveraging the impact of the clinical hypertension specialist in the local community. Am J Hypertension 2002;15:372-379.
8. Hansson L, Lindholm LH, Niskanen L. Effect of angiotensin-converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999;353:611-616.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-33.
10. Krakoff LR. Hypertension Specialists: ready or not, here we come (editorial). Am J Hypertens 1999;12:242-243.
11. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
12. Brown BG, Zhao XQ, Chait A. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592.
13. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165-175.
14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998;352:854-865.
15. Garratt KN, Brady PA, Hassinger NL. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-124.
16. Schiffrin EL, Bac Park J, Intengan HD. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist Losartan. Circulation 2000;101:1653-1665.
17. Lender D, Arauz-Pacheco C, Breen L. A double-blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertension 1999;12:298-303.
18. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991;14(suppl 4):39-47.
19. Freeman DJ, Norrie J, Naveed S. Pravastatin and the development of diabetes mellitus-evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-362.
20. Carlsen SM, Rossvoll O, Bjerve KS. Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Internal Med 1996;239:227-233.
21. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Int Med 1997;57:2413-2446.
22. Scherrer U, Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic overactivity and cardiovascular morbidity. Eur J Endocrin 2000;142:315-323.
23. Forgione MA, Leopold JA, Loscalzo J. Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol 2000;15:409-415.
24. Gokce N, Loscalzo J. Endothelial dysfunction and atherothrombosis, in Wilson PWF (ed): Atlas of Atherosclerosis-Risk Factors and Treatment. Singapore, Current Medicine Inc., 2000, ed 4, p 22.
25. Bakris GL, Williams M, Dworkin L, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in patients with hypertension and diabetes: a consensus approach. Am J Kid Dis 2000;36:646-661.
26. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA 2001; 285:2486-2497.
27. American Diabetes Association. Standards of medical care for patients with diabetes mellitus: position statement. Diabetes Care 2002:25(suppl 1):S33-S49.
28. Pawlson G. Comprehensive HEDIS measures for diabetic patients. Managed Care 9(8 suppl):5-10, 2000.
29. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to JNC VI risk stratification. Hypertension 2000;35:539-543.
30. JNC 7 Express: The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. NIH Publication No. 03-5233, May 2003.
31. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Int Med 1999;159:1104-1109.
32. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-486.
33. Benetos A, Thomas F, Bean K, et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Int Med 2002; 162:577-581.
34. Solomon AJ, Gersh BJ. Management of chronic stable angina: medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass graft surgery-lessons from the clinical trials. Ann Intern Med 1998;128:216-223.
35. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
36. Herings RMC, De Boer A, Stricker BH. Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995;345: 1195-1198.
37. Thamer M, Ray NF, Taylor T. Association between antihypertensive drug use and hypoglycemia: a case-control study of diabetic users of insulin or sulfonylureas. Clin Ther 1999;21:1387-1400.
38. Lindholm LH, Ibsen H, De vereux RB, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention For endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010.
39. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence ot type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
40. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998;6:47-53.
41. Kieren JM, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-1350.
42. Dahlof B, Devereux RB, Kjeldsen SE. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003.
43. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) trial. Lancet 1998;351:1755-1762.
44. United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J 1998;317:703-713.
45. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
46. Pyorala K, Pedersen TR, Kjekhus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care 1997;20:614-620.